Medicine for treating mesangial proliferative glomerulonephritis

A technology for treating glomerulonephritis and drugs, which is applied in the field of stem cell therapy, and can solve the problems of large toxic and side effects of cytotoxic drugs, limiting the application of hormones and cytotoxic drugs, etc.

Inactive Publication Date: 2016-11-30
GENERAL HOSPITAL OF PLA
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0003] Hormone therapy is usually accompanied by side effects of varying degrees, and cytotoxic drugs have more toxic side effects, which limits the application of hormones and cytotoxic drugs

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Medicine for treating mesangial proliferative glomerulonephritis
  • Medicine for treating mesangial proliferative glomerulonephritis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0021] Example 1Foxd1 + Effect of metanephric mesenchymal cells on mesangial proliferative glomerulonephritis

[0022] 1. Foxd1 + Preparation of metanephric mesenchymal cells

[0023] 1.1 Subculture

[0024] 1) Use Foxd1 cre Transgenic mice with DTR flox Transgenic mice were mated to screen Foxd1-cre; DTR-flox double transgenic embryonic mice at E13.5 days, and metanephric mesenchymal cells were extracted and inoculated in stem cell culture medium at 37°C, 5% CO 2 After culturing for 60-72 hours, add diphtheria toxin with a final concentration of 100-150ng / ml to the culture medium, and change the medium with stem cell culture medium containing 100-150ng / ml diphtheria toxin every 48 hours until cultured 5-7 days, when the cells are 80% confluent, passage at a ratio of 1:2;

[0025] 2) Digest the cells with 0.25% trypsin (2.5ml / 25cm 2 Culture bottle, 5ml / 75cm 2 culture flask), incubate at 37°C for 3 minutes, and stop digestion with 2 times the volume of trypsin containin...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention provides a medicine for treating mesangial proliferative glomerulonephritis and an application of the Foxd1+ metanephric mesenchyme cells to preparation of the medicine for treating the mesangial proliferative glomerulonephritis. Effective components of the medicine are Foxd1+ metanephric mesenchyme cells. The Foxd1+ metanephric mesenchyme cells are used for treating Thy1 antibody mesangial proliferative glomerulonephritis in an animal model, and results indicate that the Foxd1+ metanephric mesenchyme cells can obviously relieve pathological change of glomeruli and relieve renal function damage.

Description

technical field [0001] The invention belongs to the technical field of stem cell therapy, and in particular relates to a medicine for treating mesangial proliferative glomerulonephritis. Background technique [0002] At present, the treatment of mesangial proliferative glomerulonephritis is mainly hormone therapy and cytotoxic drug therapy. Hormone therapy inhibits the activity of transcription factor NF-κB and then inhibits the proinflammatory factors (IL-1β, TNF-α) that can promote glomerulonephritis. ), and has a therapeutic effect on various types of glomerulonephritis. [0003] Hormone therapy is usually accompanied by different degrees of side effects, and cytotoxic drugs have more toxic side effects, which limits the application of hormones and cytotoxic drugs. Therefore, scientists all over the world are working hard to conduct animal and clinical trials, hoping to find new treatments that can regulate immunity, reduce damage, promote repair, and reduce toxic and si...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K35/28A61P13/12
CPCA61K9/0019A61K35/28
Inventor 陈香美李清刚金美玲吴玲玲蔡广研冯哲
Owner GENERAL HOSPITAL OF PLA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap